Predicting palbociclib efficacy in breast cancer with organoid-derived biomarkers

High DYNLT1 expression predicts poor response to 1L palbociclib in HR+ breast cancer

INDICATION
Breast
BIOMARKER
DYNLT1

A)

 

B)

 

Kaplan-Meier survival curves showing rwPFS (A) and rwOS (B) outcomes comparison between DYNLT1-low and DYNLT1-high HR+ HER2- breast cancer patients in 1L palbociclib pre-treated samples. Shaded areas represent the 95% confidence intervals. Median survival times are specified. Cohort split on median expression level.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Three abstract data distributions displayed as shapes made of small, colored squares.

Sacituzumab govitecan and tumor microenvironment shifts in metastatic triple-negative breast cancer

2026-07-01
CXCL/SPP1 (CS)
Breast
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
A blue grid with dark blue squares forming a descending diagonal path, possibly a heatmap.

Optimizing therapy sequencing for HR+ HER2- metastatic breast cancer

2026-05-26
Breast
HER2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

ESR1 mutations and copy number loss in breast cancer

2026-05-26
Breast
ESR1